|
S-100β
Protein – Serum Levels in Children with Brain Neoplasms and its Potential as a
Tumor Marker
Anil Rajendra, Philip C. Spinella, Henry R. Drott, Troy
E. Dominguez, Leslie Sutton, Mark Helfaer
Department of Anesthesiology and
Critical Care Medicine (AR, PCS, TED, MH), Department of Pathology and
Laboratory Medicine (HRD), Department of Neurosurgery (LS), The Children's
Hospital of Philadelphia
Objective. To determine if serum S-100β
levels are elevated in children with brain neoplasms and if
it can be used as a tumor marker for children with brain neoplasms.
Design. Prospective cohort study.
Setting. Urban, tertiary care, children's teaching
hospital.
Patients. 136 healthy children and 27 children with brain neoplasms.
Methods. Serum levels of S-100β
were measured in 136 healthy children to serve as controls and 27 children with
brain neoplasms, who underwent biopsy or resection of the mass.
Patients were then classified into astrocytoma or non-astrocytoma groups.
Measurements and main results.
The median serum S-100β
level for the control group was 0.27 mcg/l
(range, 0.06–2.6 mcg/l),
and for the brain neoplasm group was 0.2 mcg/l
(range, 0.01–2.1 mcg/l),
(p = 0.09).
There were 13 children with astrocytomas and 14 with non-astrocytomas.
The S-100β
levels for the astrocytoma group was 0.25 mcg/l
(range, 0.05–1.1 mcg/l)
and for the non-astrocytoma group 0.17 mcg/l
(range, 0.01–2.1 mcg/l),
(p = 0.47).
Conclusions.
Serum S-100β
levels are not elevated in children with brain neoplasms compared to healthy
children, nor are they elevated in children with astrocytomas compared to
non-astrocytomas.
The S-100β
protein does not appear to be useful as a serum tumor marker in children with
brain neoplasms.
Keywords: astrocytomas, blood–brain barrier, brain
neoplasms, children, S-100β
protein, serum
Copyright
©
2004 Kluwer Academic Publishers.
All rights reserved
Source:
http://journals.kluweronline.com/article.asp?PIPS=5266128
|
